Olaparib is a type of breast cancer drug used to treat advanced breast cancer in women with certain genetic mutations. It is a poly ADP-ribose polymerase (PARP) inhibitor, which works by blocking the action of an enzyme that helps cancer cells repair themselves. This makes it harder for the cancer cells to survive and grow. Olaparib is used in combination with other treatments, such as chemotherapy, to help slow the growth of cancer cells. It is also used to treat metastatic breast cancer, which is cancer that has spread to other parts of the body. Olaparib is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer in women with certain genetic mutations. It is also approved in the European Union and other countries. Some companies in the Olaparib market include AstraZeneca, Merck, Pfizer, and GlaxoSmithKline. These companies are involved in the research, development, and marketing of Olaparib and other breast cancer drugs. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
